161 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: the randomized, double-blind, phase 3 ENGOT-Cx11/GOG-3047/KEYNOTE-A18 study

彭布罗利珠单抗 宫颈癌 放化疗 医学 相(物质) 肿瘤科 内科学 癌症 物理 免疫疗法 量子力学
作者
Domenica Lorusso,Yang Xiang,Kosei Hasegawa,Giovanni Scambia,Mariano Leiva,Pier Ramos-Elías,Alejandro Acevedo,Júlia Vízkeleti,Andrea Gomes,Fernando Contreras Mejía,Ari Reiss,Ali Ayhan,Jung‐Yun Lee,Valeriya Saevets,Flora Zagouri,Kan Li,Karin Yamada,Sarper Toker,Sandro Pignata,Linda R. Duska
标识
DOI:10.1136/ijgc-2024-esgo.3
摘要

Introduction/Background

Pembrolizumab has shown efficacy in patients with cervical cancer. The effect of chemoradiotherapy may be enhanced by immunotherapy. ENGOT-cx11/GOG-3047/KEYNOTE-A18 (NCT04221945) assessed efficacy and safety of pembrolizumab + concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC).

Methodology

Eligible patients with newly diagnosed, previously untreated, high-risk LACC (FIGO 2014 stage IB2-IIB with node-positive disease or stage III-IVA) were randomized 1:1 to receive 5 cycles of pembrolizumab 200 mg or placebo Q3W + CCRT, then 15 cycles of pembrolizumab 400 mg or placebo Q6W. The CCRT regimen included 5 cycles (with optional sixth dose) of cisplatin 40 mg/m2 Q1W + EBRT then brachytherapy. Patients were stratified by planned EBRT type (IMRT/VMAT vs non-IMRT/non-VMAT), stage at screening (stage IB2-IIB vs III-IVA) and planned total radiotherapy dose. Primary endpoints were PFS per RECIST v1.1 by investigator and OS.

Results

1060 patients were randomized to pembrolizumab+CCRT (n=529) or placebo+CCRT (n=531). At the protocol-specified first interim analysis (January 9, 2023, data cutoff), median follow-up was 17.9 mo (range, 0.9–31.0). Pembrolizumab+CCRT showed a statistically significant improvement in PFS vs placebo+CCRT. 24-mo PFS was 67.8% with pembrolizumab+CCRT vs 57.3% with placebo+CCRT; median PFS was not reached in either group (HR=0.70 [95% CI, 0.55–0.89; P=0.0020]); results were consistent across all prespecified subgroups. With only 103 events (42.9% maturity), the addition of pembrolizumab to CCRT showed a favorable trend in OS (HR=0.73 [95% CI, 0.49–1.07]); these data have not crossed the boundary of statistical significance. Grade ≥3 TRAE incidence was 67.0% in the pembrolizumab+CCRT group and 60.0% in the placebo+CCRT group.

Conclusion

Pembrolizumab+CCRT showed a statistically significant and clinically meaningful improvement in PFS and a favorable trend in OS compared with placebo+CCRT in patients with high-risk locally advanced cervical cancer and had a manageable safety profile. These data suggest pembrolizumab+CCRT can be considered as a new standard of care for this population.

Disclosures

Disclosures are provided via the ESGO COI Disclosure forms.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
刚刚
刚刚
张群发布了新的文献求助10
刚刚
烟花的应助被Willing采纳,获得10
刚刚
小杰发布了新的文献求助10
1秒前
fwz完成签到,获得积分10
1秒前
1秒前
sun完成签到,获得积分10
1秒前
瓷塲发布了新的文献求助10
1秒前
风中的善愁完成签到,获得积分0
2秒前
斯文败类的应助被D德采纳,获得10
2秒前
DOKEN完成签到,获得积分10
2秒前
Horizon完成签到 ,获得积分10
2秒前
2秒前
一二发布了新的文献求助20
2秒前
3秒前
深情安青的应助被甜蜜阑悦采纳,获得10
3秒前
3秒前
ada发布了新的文献求助10
3秒前
嘻嘻不嘻嘻完成签到,获得积分10
3秒前
慕青的应助被seven采纳,获得10
4秒前
一弦完成签到 ,获得积分20
4秒前
夏樱完成签到,获得积分10
4秒前
小菜一碟2021完成签到,获得积分10
4秒前
4秒前
哈哈哈发布了新的文献求助10
4秒前
xiaoling完成签到,获得积分10
5秒前
科研q发布了新的文献求助10
5秒前
自然白安完成签到 ,获得积分10
5秒前
阿辰完成签到,获得积分10
5秒前
Sapphire完成签到,获得积分10
6秒前
五米完成签到,获得积分10
6秒前
小SU哥完成签到,获得积分10
6秒前
北柒陌人完成签到,获得积分10
6秒前
7秒前
7秒前
失眠的血茗完成签到,获得积分10
7秒前
joker完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159480
求助须知:如何正确求助?哪些是违规求助? 9554975
关于积分的说明 21723753
捐赠科研通 7749303
什么是DOI,文献DOI怎么找? 3427226
关于科研通互助平台的介绍 2552227
邀请新用户注册赠送积分活动 2471592